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Identiﬁcation of genes and gene pathways associated with
major depressive disorder by integrative brain analysis of rat
and human prefrontal cortex transcriptomes
K Malki1,5, O Pain1,5, MG Tosto1,2, E Du Rietz1, L Carboni3 and LC Schalkwyk4
Despite moderate heritability estimates, progress in uncovering the molecular substrate underpinning major depressive disorder
(MDD) has been slow. In this study, we used prefrontal cortex (PFC) gene expression from a genetic rat model of MDD to inform
probe set prioritization in PFC in a human post-mortem study to uncover genes and gene pathways associated with MDD. Gene
expression differences between Flinders sensitive (FSL) and Flinders resistant (FRL) rat lines were statistically evaluated using the
RankProd, non-parametric algorithm. Top ranking probe sets in the rat study were subsequently used to prioritize orthologous
selection in a human PFC in a case–control post-mortem study on MDD from the Stanley Brain Consortium. Candidate genes in the
human post-mortem study were then tested against a matched control sample using the RankProd method. A total of 1767 probe
sets were differentially expressed in the PFC between FSL and FRL rat lines at (q⩽ 0.001). A total of 898 orthologous probe sets was
found on Affymetrix’s HG-U95A chip used in the human study. Correcting for the number of multiple, non-independent tests, 20
probe sets were found to be signiﬁcantly dysregulated between human cases and controls at q⩽ 0.05. These probe sets tagged the
expression proﬁle of 18 human genes (11 upregulated and seven downregulated). Using an integrative rat–human study, a number
of convergent genes that may have a role in pathogenesis of MDD were uncovered. Eighty percent of these genes were
functionally associated with a key stress response signalling cascade, involving NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells), AP-1 (activator protein 1) and ERK/MAPK, which has been systematically associated with MDD, neuroplasticity and
neurogenesis.
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INTRODUCTION
Major depressive disorder (MDD) is a severe psychiatric disease
providing a signiﬁcant contribution to the global burden of
disease.1,2 Endeavours to identify factors underlying the molecular
basis of MDD have been guided by quantitative studies reporting
a substantial genetic contribution to its development.3 However,
as with other Axis-I psychiatric disorders, progress in identifying
the genetic variation associated with the pathology have been
slow.4,5
One approach for studying the molecular mechanism of MDD in
disease-relevant brain regions is by exploring messenger RNA
(mRNA) changes in animal models.6 The identiﬁcation of
differentially expressed genes can provide early clues into the
molecular mechanisms associated with the pathology in humans.
However, the exploration of the human brain transcriptome has
major limitations, namely the sample limitations, including the
requirement of post-mortem brain tissue and confounding
factors.7 Indeed, several studies have demonstrated the advantage
of using animal models of disease to inform human studies by
providing a hypothesis-free candidate genes selection with higher
prior probability of being involved in the human pathology.6,8,9
In this study, we explored expression differences between
Flinders Sensitive or Resistant Lines (FSL/FRL) of rat, which
represent one of the most robust genetic models of MDD.10
Flinders rat have been selectively bred to display a high sensitivity
to diisopropyl ﬂuorophosphates and cholinergic agents, mimick-
ing an established neurobiological feature of MDD in humans.11 In
addition, these lines have been reported to exhibit a number of
other characteristic biological and behavioural features of
MDD.10,12
By identifying differentially expressed genes between FSL and
FRL lines, it is possible to guide candidate gene selection for
subsequent analysis in human post-mortem samples.8 A recently
published study from the Genome-based Therapeutic Drugs for
Depression (GENDEP) consortium previously explored hippocam-
pal expression differences by adopting this approach.8 However
prefrontal cortex (PFC) expression proﬁles are now available and
existing evidence demonstrates that abnormalities have been
repeatedly reported in MDD patients in this brain region.13,14
Therefore, we followed a similar design to investigate gene
expression changes in PFC. In this study, identiﬁcation of
differentially expressed genes in the PFC of FSL/FRL was used to
inform probe set selection in a comparable human PFC mRNA
data set. We hypothesized that a set of genes differentially
expressed in the genetic rat MDD model would also be
differentially regulated in a human, case–control study on MDD.
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MATERIALS AND METHODS
Design
This study used transcriptomic data derived from the PFC of a rat model of
MDD, investigated within the GENDEP project (http://gendep.iop.kcl.ac.uk),
to guide candidate gene selection for subsequent analysis within a
comparable post-mortem case–control study on MDD from the Stanley
Brain Consortium (http://www.stanleyresearch.org). GENDEP is a multi-
centre pharmacogenetic project consisting of a series of studies involving
humans, animal models and in vitro experiments. GENDEP design was
aimed at performing an integrative analysis of key processes to provide
insight into the molecular mechanisms underlying MDD and the
differential response to antidepressant treatment. One subgroup of rodent
studies within the GENDEP project involved comparison of mRNA levels in
the PFC of FSL and FRL rat lines, a robust model of ‘endogenous’
depression. Candidate modulated genes identiﬁed in the animal model
were subsequently validated in human samples. The case–control study of
MDD by the Stanley Brain Consortium similarly collected information of
key molecular processes within post-mortem tissue derived from
participants using exclusion criteria which can be found on the Stanley
Brain Consortium website (http://www.stanleyresearch.org).
Animals
This study used 39 adult rats consisting of two strains, 17 FSL and 22 FRL.15
Rats were bred in Stockholm at the Karolinska Institutet. Animal
maintenance and experimental procedures were conducted in accordance
to the European Communities Council Directive of 24 November 1986.
Human samples
This study used human samples, which have been made available to
researchers worldwide, after being donated to the Stanley Foundation
Brain Collection in MD, USA. The data were downloaded from the Gene
Expression Omnibus (accession ID: GSE12654; www.ncbi.nlm.nih.gov/geo).
Dissection of PFC tissues (Brodmann’s Area 10) and microarray procedures
were carried out by Iwamoto et al.16 Post-mortem PFCs from individuals
diagnosed with MDD were carefully matched with controls. Diagnoses of
MDD were in accord with the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition.17 Controls were matched by age, gender, race,
pH, post-mortem interval and quality of mRNA extraction. Consistent with
previous studies using this data set,16 samples were excluded if mRNA
quality was poor and individuals were465 years of age leading to a total
of 26 human PFC samples (11 cases and 15 controls) being used. Further
information on the human data and original microarray procedure can be
found elsewhere.16
mRNA extraction and lab protocols
This study used raw gene expression (.CEL) ﬁles from data collected
previously. PFC mRNA protocols extraction from Flinders rats has been
described elswhere.15 cRNA was hybridized to Affymetrix Rat Genome 230
2.0 arrays (Santa Clara, CA, USA). The Affymetrix Rat Genome 230 2.0
GeneChip provides a comprehensive coverage of the rat genome
containing 31,000 probe sets representing 28,000 genes.
Information on The Stanley Foundation human brain collection and
Neuropathology Consortium can be found elsewhere.18 PFC (Brodmann’s
Area 10) tissue using the Trizol method and then puriﬁed using the Qiagen
RNeasy kit (Hilden, Germany). RNA (8–10 mg) was used to synthesize
cDNA, which was then used to generate cRNA. PFC (Brodmann’s Area 10)
cRNA was hybridized onto the Affymetrix HG-U95A. A detailed description
of the microarray procedure has been previously described by Iwamoto
et al.16
Statistical analysis procedure
Rat data set: Raw.CEL ﬁles for FSL and FRL rats were downloaded from the
Gene Expression Omnibus (GEO; accession number GS2088; www.ncbi.
nlm.nih.gov/geo). Initially raw data was normalized and summarized using
RMA (Robust Multichip Averaging), returning log2 transformed
intensities.19 The rat data were collected in two cohorts requiring ComBat
merging function within the inSilicoMerging package to avoid potential
batch effects.20 To identify top differentially expressed probe sets within
the summarized data, the PRadvance function within the RankProd
package was used.21 P-values of differential expression were determined
using 10 000 permutations. To select a list of candidate genes to carry
forward for human analysis, a conservative false discovery rate (pfp,
percentage false positive) threshold of Po0.001 and a fold change 41.5
was used. To match probe sets between rat and human data sets, gene
symbols were used. A list of gene symbols corresponding to signiﬁcant rat
probe sets was determined using PANTHER (http://www.pantherdb.org).
Human data set: The raw.CEL ﬁles for the control and MDD diag-
nosed human post-mortem samples were downloaded from the Gene
Expression Omnibus (accession ID: GSE12654; www.ncbi.nlm.nih.gov/geo).
Initially raw data were normalized and summarized using RMA, returning
log2 transformed intensities.
19 Human genes orthologous to the candidate
genes selected by prior rat data set analysis were determined using the
NetAffx Rat 230 v2 orthologue annotation. Top differentially expressed
genes between the control and MDD individuals determined using
the PRadvance function within the RankProd package was used.21 A
signiﬁcance threshold of pfp o0.05 was calculated using 10 000
permutations. Fold change in expression was calculated manually for
MDD-associated probes.
Probe sets differentially expressed in the human sample were
subsequently uploaded to the Ingenuity Pathway Analysis (IPA) software.
The IPA software was used for its ability to analyse mRNA data in the
context of known biological response and regulatory networks. IPA returns
a score for each network using a P-value based on Fisher’s exact test. The
software determines the probability that each biological function assigned
to that data set was due to chance alone.
RESULTS
First, we statistically evaluated mRNA differences between Flinders
Sensitive and Resistant rats. The RankProd non-parametric
algorithm uncovered 1767 probe sets on the Affymetrix Rat
Genome 230 2.0 Gene Chip, differentially regulated at the
stringent signiﬁcance threshold of pfp ⩽ 0.001, and a fold change
⩾ 1.5. Given the potential for false positives, a conservative
threshold was preferred to prioritize probe sets with higher prior
probability of association with MDD in the human study. The
results from the rat study were used to provide a list of candidate
probe sets for RankProd analysis in the human data set. A total of
898 probes sets, tagging the expression proﬁle of the genes
orthologous to ones differentially expressed in rat, were also
found on Affymetrix’s HG-U95A chip using the NetAffx tool from
Affymetrix.
We then obtained a subset of the human mRNA data set to
include only those probe sets prioritized from the animal study. To
statistically evaluate differences between post-mortem MDD cases
and controls, we used the PRadvance function in the RankProd
function using the single origin option. RankProd analysis of
human data set uncovered 18 probe sets differentially expressed
in the PFC between humans diagnosed with MDD and control at
the corrected signiﬁcant threshold of (pfp ⩽ 0.05, P-value
⩽ 6 × 10−4, Table 1). A graph showing the distribution of pfp
values for up- and downregulated probe sets can be found in
Supplementary Figure 1.
The analysis uncovered a total of 15 genes, 11 signiﬁcantly
upregulated and four signiﬁcantly downregulated in MDD cases
versus control. The list includes several genes previously
implicated in depression including the NTRK2, AXL and TAC1
genes. Affymetrix’s arrays are designed to have multiple probe
sets tagging the expression of different genes in the 3’-UTR region.
Different probe sets tagging the expression of the same genes
were among the top ranking probe sets further reducing the
chance of false positives. The fold change of signiﬁcant probes
ranged from 1.18 to 1.80. As the ﬁndings are in human brain,
moderate fold changes in gene expression are expected due to
large heterogeneity and the relatively sensitive neural environ-
ment. Last, we uploaded all 20 probes sets on the IPA software.
Nineteen probe sets were mapped to the ingenuity reference
database and carried forward for analysis. The top ranking
pathway returned by IPA, with a score of 26 and included 12
out of 15 reference molecules uploaded. The majority of the genes
uncovered (80%) are signiﬁcantly associated with same network
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centred on the NF-κb (nuclear factor kappa-light-chain-enhancer
of activated B cells), MapK and ERK signalling cascade. This
neurogenetic-neurotrophic pathway is of particular interest and
relevance as it has been extensively associated with MDD and
stress response.
DISCUSSION
This study has used transcriptomic data derived from the PFC of
FSL and FRL rat strains to guide candidate gene selection in
human samples generated in the corresponding brain region and
subsequently identify molecular dysregulations associated with
MDD in the PFC of humans. Analysis of differential gene
expression within the PFC of the selectively bred FSL and FRL
strains, a robust model of MDD, provided an appropriate number
of candidate genes to be then validated in the more relevant
human data set. The analysis of differential gene expression in the
PFC of individuals diagnosed with MDD or controls, using the
candidate gene selection, provided a list of genes and biological
pathways associated with MDD.
IPA identiﬁed a functional pathway involving 80% of the genes
signiﬁcantly associated with MDD in humans (Figure 1). This
pathway was centred on key stress response signalling molecules,
such as NF-κB, AP-1 (activator protein 1) and several MAPKs
(mitogen activated protein kinases). These MAPKs function to
cascade signals, in response to extracellular stimuli, regulating the
activity of a number of transcription factors including AP-1 and NF-
κB (Figure 1). Taking NF-κB as an example, upon activation, the
transcription factor translocates into the nucleus where it binds to
target DNA sequences (kB sites). NF-κB binding to these motifs
results in the transcriptional regulation of a large number of pro-
inﬂammatory genes encoding proteins such as cytokines.22 As a
result of such processes, a range of other downstream pathways
are modulated to adapt cellular/tissue function with regard to the
transduced signals. In particular, pathway analysis identiﬁed
downstream neuroplasticity and neurogenesis pathways as
dysregulated in the PFC of MDD individuals. These neurogenetic
pathways involved a number of genes identiﬁed by our RankProd
analysis (for example, NTRK2, AXL and CNTN1) as well as molecules
based upon functional enrichment (for example, vascular
endothelial growth factor). Supporting the validity of this
enrichment, vascular endothelial growth factor has been pre-
viously implicated in hippocampal neurogenesis and response to
stress.23,24 This powerful approach for the enrichment of probe
sets has been able to encapsulate and support a molecular model
of depression involving inﬂammation-mediated dysregulation of
neuroplasticity and neurogenesis. Further support of this inter-
pretation of the ﬁndings is apparent when the differentially
regulated genes returned by RankProd analysis are functionally
annotated separately.
A number of genes differentially regulated in MDD individuals
indicate increased activation of stress and oxidative response
pathways in the PFC. Two probes within PKCI (protein kinase C
Iota) were identiﬁed as upregulated in MDD. PKCI encodes a
serine/threonine protein kinase, which has been reported to
regulate NF-κB activity and neurotrophin-mediated neuronal
differentiation and survival via neuronal growth factor.25
PKCI has been previously associated with MDD in a previous
analysis using the same human data set.26 PKCI has also been
determined as upregulated in suicidal individuals, compared with
non-suicidal individuals, both with mood disorders.27 These
ﬁndings support PKCI as a modulator of mood disorders.
Another gene associated with MDD involved in the stress
response is DDIT4. DDIT4 (DNA-damage-inducible transcript 4),
also known as REDD1, is an inhibitor of mTORC1 (mammalian
target of rapamycin complex-1) and it is regulated by oxidative
stress. Recent ﬁndings demonstrated DDIT4 involvement:28 DDIT4
was activated in the PFC of rats in response to stress, viral-
mediated upregulation of DDIT4 in the PFC of rats induced
depressive-like and anxiety-like behaviours, and the analysis of
different post-mortem MDD samples showed an upregulation of
DDIT4 in the PFC of MDD individuals. Our ﬁndings are in
agreement with the upregulation of DDIT4 in the PFC of MDD
patients, highlighting the potential importance of mTORC1 path-
ways in MDD.
One of the main theories of the pathophysiology of MDD
asserts that the exposure to chronic stress alters transcriptional
regulation of growth factors and hormones leading to impaired
neurogenesis and neuroplasticity.29 According to this theory,
following our ﬁndings of altered stress response pathways, genes
Table 1. Table shows probe ID, gene title, gene symbol, FC (fold change), pfp (percentage of false positives) and P-value for probes signiﬁcantly
associated with MDD
Probe ID Gene title Gene symbol FC pfp P-value
Upregulated probe sets
31525_s_at Haemoglobin, alpha 1 /// haemoglobin, alpha 2 HBA1 /// HBA2 1.80 0.0E+00 o1.00E− 06
32052_at Haemoglobin, beta HBB 1.67 0.0E+00 o1.00E− 06
31687_f_at Haemoglobin, beta HBB 1.65 0.0E+00 o1.00E− 06
40928_at WD repeat and SOCS box containing 1 WSB1 1.35 9.2E− 03 o1.00E− 06
38280_s_at Neurotrophic tyrosine kinase, receptor, type 2 NTRK2 1.28 1.1E− 02 1.00E− 04
1603_g_at Protein kinase C, iota PRKCI 1.35 1.7E− 02 1.00E− 04
33182_at Neurotrophic tyrosine kinase, receptor, type 2 NTRK2 1.27 2.5E− 02 2.00E− 04
31809_at Contactin 1 CNTN1 1.22 2.3E− 02 2.00E− 04
36059_at Low density lipoprotein receptor-related protein 4 LRP4 1.31 3.1E− 02 3.00E− 04
1602_at Protein kinase C, iota PRKCI 1.32 3.0E− 02 3.00E− 04
33364_at Phosphodiesterase 4D interacting protein PDE4DIP 1.22 2.7E− 02 3.00E− 04
32786_at jun B proto-oncogene JUNB 1.33 2.6E− 02 4.00E− 04
1278_at AXL receptor tyrosine kinase AXL 1.28 3.8E− 02 6.00E− 04
39827_at DNA-damage-inducible transcript 4 DDIT4 1.27 3.8E− 02 6.00E− 04
Downregulated probe sets
36363_at UDP glycosyltransferase 8 UGT8 1.22 2.0E− 04 o1.00E− 06
36490_s_at Phosphoribosyl pyrophosphate synthetase 1 PRPS1 1.28 2.2E− 02 o1.00E− 06
41193_at Dual speciﬁcity phosphatase 6 DUSP6 1.18 2.0E− 02 1.00E− 04
36254_at Tachykinin, precursor 1 TAC1 1.27 3.2E− 02 1.00E− 04
Abbreviation: MDD, major depressive disorder.
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involved in neuroplasticity and neurogenesis were also expected
to be differentially expressed. Compelling evidence showed an
association between dysregulation of neurotrophic pathways,
impaired neuronal plasticity and MDD.30,31 The neuroplastic
functions of the neurotrophic pathway are centred on brain-
derived neurotrophic factor (BDNF), its receptor neurotrophic
tyrosine receptor kinase type 2 (NTRK2 or TrkB) and the
transcription factor cAMP (cyclic adenosine monophosphate)
binding protein 1 (CREB1) which regulates both the expression
of BDNF and the TrkB gene.32 In this study, two key genes in the
neurotrophic pathway were associated with MDD in the PFC, in
agreement with this theory. In our results, the clearest evidence
for the dysregulation of neurotrophic pathways in MDD comes
from the ﬁnding of an upregulation of the NTRK2 gene in MDD
patients as shown by two probes. The NTRK2 gne encodes the
neurotrophic tyrosine receptor kinase type 2 (TrkB), which binds
BDNF as well as other neurotrophins, including NT-4 (neurotro-
phin-4) and NT-3 (neurotrophin-3). Previous studies have reported
that antidepressant treatment leads to an upregulation of BDNF
expression and activation of NTRK2 via CREB1.33,34 Moreover,
Figure 1. Network uncovered using IPA. The network includes 12 out of the 15 genes uploaded on the Ingenuity Pathway Analysis reference
database. These genes are functionally related and have a role in the same network centred on NF-κb, MAPK and ERK signalling cascade. This
network has previously been implicated in both MDD studies and in studies on response to antidepressant treatment. Genes central to the
stress response signalling cascade have been highlighted in red. Genes identiﬁed as differentially expressed in MDD individuals have been
highlighted: pink indicated upregulation and blue indicates downregulation. IPA, Ingenuity Pathway Analysis; MDD, major depressive
disorder; NF-κb, nuclear factor kappa-light-chain-enhancer of activated B cells.
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genetic variation within and downregulation of NTRK2 in the PFC
has been associated with suicidal ideation and suicide,35,36
supporting the role of NTRK2 in depressive symptoms.
Another gene signiﬁcantly upregulated in MDD patients was
PDE4DIP (phosphodiesterase 4D interacting protein). PDE4DIP’s
function is to compartmentalize PDE4D within the cAMP
pathway.37 PDE4 proteins degrade cAMP and are important for
the regulation of intracellular cAMP concentrations. Antidepres-
sant effects exerted by PDE4 inhibitors through the enhancement
of cAMP signalling are mainly attributable to the inhibition of
PDE4D.38 It is conceivable that our ﬁnding of PDE4DIP
upregulation in MDD individuals indicates increased compart-
mentalization of PDE4D leading to altered cAMP availability. This
provides a link between PDE4DIP and neurotrophin regulation via
CREB1.
The AXL gene, encoding AXL receptor protein-tyrosine kinase
(RPTK) was shown in our analysis to be upregulated in MDD
individuals. This subfamily of RPTKs has been less well character-
ized in the brain than the previously discussed neurotrophic
receptor tyrosine kinases. The AXL RPTKs acts as the receptor for
Gas6 (growth arrest-speciﬁc gene-6), which is expressed through-
out the adult central nervous system. A study investigating the
function of AXL RTPKs in the adult rat brain suggested a role in
neuronal survival and growth, and regulating synaptic function
and plasticity.39 Further research is required to determine the
extent to which these RPTKs regulate the molecular mechanisms
of depression, however, the AXL gene identiﬁed as a biomarker for
depressive symptoms in elderly individuals.40
TAC1 (tachykinin, precursor 1), reported as downregulated in
MDD individuals, is a complex gene encoding four proteins within
the tachykinin hormone family. These four proteins, called
substance P, neurokinin A, neuropeptide K and neuropeptide
gamma, function as neurotransmitters and neuromodulators. Our
ﬁnding is supported by a study reporting that Tac1 knockout in
mice led to reduced anxiety-like and depression-like behaviours.41
In addition, antagonists of the tachykinin receptor, called TACR1,
have been investigated in clinical trials for depression with mixed
results.42 Research of TACR1 antagonists is still under investigation
for antidepressant potential. Further research into the protein
products of TAC1 and other neurokinins could provide insight into
the molecular mechanisms of MDD.
DUSP6 (dual-speciﬁcity protein phosphatase 6) was identiﬁed in
this study, as downregulated in the PFC of MDD individuals. The
downregulation of DUSP6 has also been reported in the PFC of
individuals with bipolar disorder.43 Furthermore, genetic variation
within and proximal to DUSP6 has been associated with bipolar
disorder and lithium-induced ERK activation,44 a mechanism
related to neuroplasticity and neurogenesis,45 suggesting a role
for DUSP6 in the regulation of mood disorders, neuroplasticity and
neurogenesis.
Another pathway implicated in depression with effects on
neuroplasticity and neurogenesis is under the regulation of the
growth factor erythropoietin, both independent and dependent
on its role in haematopoiesis.46,47 Our results provide some
evidence that erythropoietic pathways are altered in MDD
individuals with the three most signiﬁcantly upregulated probe
sets representing two genes, HBA and HBB (haemoglobin alpha
and beta). This ﬁnding is quite interesting as it could be
interpreted in a number of ways. It is possible that the
upregulation of these haemoglobin genes is indicative of an
increased concentration of haemoglobin in the PFC of individuals
with MDD. However, another more likely interpretation of these
ﬁndings includes a negative feedback loop where decreased
haemoglobin in the PFC of individuals with MDD initiates an
upregulation of haemoglobin genes. For example hypoxia induces
an upregulation of HIF1 (hypoxia inducible factor) and subse-
quently HBA and HBB.48,49
Low levels of systemic haemoglobin have symptoms of high
levels of fatigue and lethargy, similar to symptoms seen in some
depressed individuals. Low peripheral haemoglobin levels in
cancer patients have been reported to correlate with severity of
depression,50 even when controlling for severity of cancer.51
Moreover, it was reported that a low level of haemoglobin was a
signiﬁcant risk factor for post-partum depression even when
controlling for confounding variables such as delivery complica-
tions and perinatal blood loss.52 However, measures of haemo-
globin in the brain would be required to establish a connection
with depression. One study used near-infrared spectroscopy to
measure concentrations of oxygenated haemoglobin, as a
parameter for activity, in the PFC of MDD individuals and
controls.53 This study reported a signiﬁcant decrease in oxyge-
nated haemoglobin in the PFC of MDD individuals, particularly in
Brodmann’s area 10. This ﬁnding and our result of upregulated
haemoglobin genes in Brodmann’s area 10 suggest low levels of
anaemia in the PFC of depressed individuals requiring further
research. It is possible that if this anaemia does occur in the brain,
it could initiate stress response pathways via hypoxia-induced
factors.54
Strengths and limitations
The ﬁrst limitation to this study is its use of post-mortem tissue for
the isolation of human PFC RNA. RNA rapidly degrades and
therefore isolation must be carried out carefully to preserve the
quality of the sample. In addition, due to the environmental
sensitivity of gene expression, the process of death could cause
global transcriptomic changes throughout the body creating
artefacts in the results. However, without the use of post-mortem
tissue, it is not possible to extract RNA from MDD-relevant brain
tissue in humans. We have applied an integrative cross-species
approach, which helps to overcome these issues by selecting
candidate genes from the analysis of the FSL model in which
relevant brain tissue is accessible and environmental factors can
be controlled. Although relatively stringent thresholds were used
throughout the analysis, further replication of ﬁndings may be
required.
Second, the use of an animal model to study complex beha-
vioural phenotypes in humans is limited, due to the impossibility
to reproduce all the complex features of a psychiatric disease in
rodents. However animal models have been shown to be an
important source of information for the study of depression and
antidepressant treatment response in humans.9
Third, although we used a cross-validation method by exploring
mRNA differences across different studies, veriﬁcation of ﬁndings
with other experimental methods such as quantitative PCR would
have been desirable; results should be interpreted in light of this
limitation.
Last, the human data were derived from just one subsection of
the PFC; Brodmann’s area 10, meaning this study was unable to
see how gene expression changes associated with MDD varied in
other subsections of the PFC.
In summary, the ﬁndings highlight the importance of stress
response pathways leading to altered regulation of neurogenetic
and neurotrophic pathways such as the neurotrophin and
neurokinin pathways, supporting previous reports of increased
stress response and impaired neuroplasticity underlying the
pathophysiology of MDD. Further research on the mechanism
by which these molecules alter depressive behaviour could
improve prevention, diagnosis and treatment of MDD.
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